Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302067 · ClinicalTrials.gov registry record · Phase 4
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,012
- Enrollment target
NCT01302067: Completed Phase 4 study, sponsored by Pfizer.
NCT01302067 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 2,012 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (288% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01302067, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,012 participants
- Enrollment target
Study Summary
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower dose. The study also assesses the side effects and safety of the two doses.
Primary Outcome
UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Interventions
- DRUG Placebo
- DRUG Fesoterodine 8mg
- DRUG Fesoterodine 4mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,012 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
What the finished NCT01302067 record still lists
NCT01302067 is an interventional study that assigns participants to a tested intervention. Its 2,012 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (288% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01302067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01302067 about?
NCT01302067 is a clinical study titled "A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine". This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower...
What is the current status of trial NCT01302067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,012 participants. The study started on 2011-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01302067?
The interventions under investigation include: Placebo (DRUG), Fesoterodine 8mg (DRUG), Fesoterodine 4mg (DRUG).
Who is sponsoring clinical trial NCT01302067?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01302067's enrollment target sits among peer trials
2,012 36th of 2000 higher than 1,965 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia